@parkevtatevosiancfa9544
YouTube
Avg. Quality
73
Success Rate
18.41
Analysis
755
Correct
139
Fail
498
Pending
118
Ineffective
0
Total Quality
Score
If You Had Traded on This Analysis…
Correct
LLY
Long Entry
749.3500
2025-09-15
16:45 UTC
Target
850.0000
In 3 Weeks
Fail
680.0000
Risk/Reward
1 : 1
Turn Signals into Profit
Join Tahlil Plus Pro to unlock full performance history, live alerts, and AI-backed risk tools.
Start Free
Final PnL
13.43%
P/L: —
Turn Signals into Profit
Join Tahlil Plus Pro to unlock full performance history, live alerts, and AI-backed risk tools.
Start Free
The video discusses three undervalued healthcare stocks: Eli Lilly (LLY), Novo Nordisk (NOVOB), and Pfizer (PFE). LLY is trading at a forward P/E of 27, NOVOB at 15, and PFE at 8.5. Revenue growth over the past decade has been positive for all three, with LLY and NOVOB demonstrating revenue growth due to weight loss and diabetes treatments. Operating profit margins are 48% for NOVOB and 43% for LLY with a return on invested capital around 30% .PFE's operating margin now at 28% and the returns on invested capital is 9.3%. The speaker highlights that an ability to research and develop new treatments. All the 3 stocks are a long-term opportunities.
